UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

European journal of cancer (1990), 2009-07, Vol.45 (11), p.1959-1968

2009

Volltextzugriff (PDF)

Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib

Annals of oncology, 2007-09, Vol.18 (suppl-10), p.x11-x19

2007

Volltextzugriff (PDF)

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

British journal of cancer, 2015-03, Vol.112 (7), p.1199-1205

2015

Volltextzugriff (PDF)

Regulation of p53 expression by the RAS-MAP kinase pathway

Oncogene, 2001-05, Vol.20 (20), p.2527-2536

2001

Volltextzugriff (PDF)

Mechanisms of G2 arrest in response to overexpression of p53

Molecular biology of the cell, 1999-11, Vol.10 (11), p.3607-3622

1999

Volltextzugriff (PDF)

Human placental alkaline phosphatase as a histochemical marker of gene expression in transgenic mice

Transgenic research, 1996-11, Vol.5 (6), p.459-466

1996

Volltextzugriff (PDF)

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2006-01, Vol.24 (1), p.16-24

2006

Volltextzugriff (PDF)

Prevention of prostate cancer: Prostate cancer

Hematology/oncology clinics of North America, 2001-06, Vol.15 (3), p.445-457

2001

Volltextzugriff (PDF)

Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4079-4079

2011

Volltextzugriff (PDF)

Use of human placental alkaline phosphatase transgenes to detect somatic mutation in mice in situ

Methods (San Diego, Calif.), 1998-09, Vol.16 (1), p.49

1998

Volltextzugriff (PDF)

Cell cycle dependence of radiation-induced homologous recombination in cultured monkey cells

Mutation research, 1997-03, Vol.374 (2), p.233-243

1997

Volltextzugriff (PDF)

Resveratrol-Induced Gene Expression Profiles in Human Prostate Cancer Cells

Cancer epidemiology, biomarkers & prevention, 2005-03, Vol.14 (3), p.596-604

2005

Volltextzugriff (PDF)

Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): Analysis of correlations with outcome and tumor imaging parameters

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.4593-4593

2008

Volltextzugriff (PDF)

Novel Pathways Associated with Bypassing Cellular Senescence in Human Prostate Epithelial Cells

The Journal of biological chemistry, 2002-04, Vol.277 (17), p.14877-14883

2002

Volltextzugriff (PDF)

Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification

BMC cancer, 2003-02, Vol.3 (1), p.3-3, Article 3

2003

Volltextzugriff (PDF)

Reg IV: A Promising Marker of Hormone Refractory Metastatic Prostate Cancer

Clinical cancer research, 2005-03, Vol.11 (6), p.2237-2243

2005

Volltextzugriff (PDF)

Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.10554-10554

2008

Volltextzugriff (PDF)

Evaluation of soluble KIT (sKIT) as a potential surrogate marker for TTP in sunitinib malate (SU)-treated patients (pts) with advanced GIST

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.10007-10007

2007

Volltextzugriff (PDF)

Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.4045-4045

2006

Volltextzugriff (PDF)

Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.578-578

2006

Volltextzugriff (PDF)

Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.9036-9036

2005

Volltextzugriff (PDF)

In situ detection of frameshift mutation in mouse cells

Mutation research, 1998-11, Vol.421 (2), p.163-178

1998

Volltextzugriff (PDF)

Microarray-analysis of global androgen receptor co-regulator expression patterns in cultures derived from human urogenital tissues

Experimental and clinical endocrinology & diabetes, 2004, Vol.112 (S 1)

2004

Volltextzugriff (PDF)

In situ detection of frameshift mutations in mouse cells

Mutation research, 1998-11, Vol.421 (2), p.163-178

1998

Volltextzugriff (PDF)

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2008-08, Vol.26 (22), p.3743-3748

2008

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(52)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

Regulation of p53 expression by the RAS-MAP kinase pathway

Mechanisms of G2 arrest in response to overexpression of p53

Human placental alkaline phosphatase as a histochemical marker of gene expression in transgenic mice

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Prevention of prostate cancer: Prostate cancer

Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors

Use of human placental alkaline phosphatase transgenes to detect somatic mutation in mice in situ

Cell cycle dependence of radiation-induced homologous recombination in cultured monkey cells

Resveratrol-Induced Gene Expression Profiles in Human Prostate Cancer Cells

Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): Analysis of correlations with outcome and tumor imaging parameters

Novel Pathways Associated with Bypassing Cellular Senescence in Human Prostate Epithelial Cells

Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification

Reg IV: A Promising Marker of Hormone Refractory Metastatic Prostate Cancer

Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis

Evaluation of soluble KIT (sKIT) as a potential surrogate marker for TTP in sunitinib malate (SU)-treated patients (pts) with advanced GIST

Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3

Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer

Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST

In situ detection of frameshift mutation in mouse cells

Microarray-analysis of global androgen receptor co-regulator expression patterns in cultures derived from human urogenital tissues

In situ detection of frameshift mutations in mouse cells

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

Suchergebnisse filtern